Alignment Healthcare (ALHC) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Progyny (PGNY) has outperformed Alignment Healthcare (ALHC) over the past year, gaining 35.2% versus a loss of 50.8%. Over five years, PGNY leads with a -50.3% price change compared with -53.2% for ALHC. Progyny is the larger company by market cap ($2.14 billion vs $1.81 billion), about 1.2 times the size, while Alignment Healthcare is growing revenue faster (+46.1% vs +10.4%).
On valuation, Alignment Healthcare trades at a lower forward P/E (11.9x vs 12.0x for Progyny). Progyny converts more of its revenue into profit, with a net margin of 4.5% versus -0.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALHC | PGNY |
|---|---|---|
| Share price | $8.71 | $27.83 |
| Market cap | $1.81B | $2.14B |
| 1-day change | +1.87% | +1.02% |
| YTD return | -55.90% | +8.37% |
| 1-year return | -50.76% | +35.23% |
| 5-year return | -53.22% | -50.29% |
| P/E ratio (TTM) | 45.84 | 30.25 |
| Forward P/E | 11.85 | 12.00 |
| EPS (TTM) | $0.19 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.95B | $1.29B |
| Revenue growth (YoY) | +46.06% | +10.40% |
| Net income (latest FY) | $-724.00K | $58.52M |
| Gross margin | — | 23.63% |
| Operating margin | 0.37% | 6.62% |
| Net margin | -0.02% | 4.54% |
| 52-week high | $25.12 | $33.07 |
| 52-week low | $7.37 | $16.10 |
| Distance from 52-week high | -65.33% | -15.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +135.82% | +23.68% |
| Average volume | 7.55M | 1.15M |
| Shares outstanding | 207.44M | 76.73M |
| Employees | 1,849 | 835 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGNY has outperformed ALHC by 86.0 percentage points over the past year.
- Alignment Healthcare trades at a higher earnings multiple (45.8x vs 30.3x trailing P/E).
- Alignment Healthcare grew revenue faster in its latest fiscal year (+46.06% vs +10.40%).
About Alignment Healthcare
ALHC stock →Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States.
Health Care · Medical Specialities · 1,849 employees
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
ALHC vs PGNY FAQ
Which is bigger, Alignment Healthcare or Progyny?
Progyny (PGNY) is larger, with a market capitalization of $2.14B compared with $1.81B for Alignment Healthcare (ALHC).
Which stock has performed better over the past year, ALHC or PGNY?
PGNY returned +35.23% over the past 12 months, compared with -50.76% for ALHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALHC or PGNY?
PGNY has the lower trailing P/E at 30.3, versus 45.8 for ALHC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alignment Healthcare and Progyny in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Alignment Healthcare and Misc Health and Biotechnology Services for Progyny.